Telluride Dental P.c. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 126 West Colorado Ave., Suite 203, Telluride, CO 81435 Phone: 970-728-4336 Fax: 970-369-4386 |
Gary E. Conrad Dds Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 126 West Colorado Ave, Suite 203, Telluride, CO 81435 Phone: 970-728-4336 Fax: 970-369-4386 |
Elevated Dental Dentist Medicare: Not Enrolled in Medicare Practice Location: 101 E Colorado Ave, Suite 202, Telluride, CO 81435 Phone: 970-728-3665 Fax: 970-728-6589 |
News Archive
Boston Scientific Corporation today announced the completion of its acquisition of Asthmatx, Inc. of Sunnyvale, California. The transaction follows the definitive agreement announced on September 20. Under the terms of the agreement, Boston Scientific purchased all outstanding Asthmatx shares for a total of $193.5 million. Additional payments of up to $250 million are contingent upon achievement of specified revenue-based criteria through 2019. Asthmatx is now an indirect, wholly-owned subsidiary of Boston Scientific.
Immunizing children and adolescents with inactivated influenza vaccine resulted in reduced rates of influenza in their community compared to a similar community in which children did not receive the vaccine, suggesting that vaccinating children may help prevent transmission of the virus and offer protection for unimmunized community residents, according to a study in the March 10 issue of JAMA.
At birth, your body was 100-percent human in terms of cells. At death, about 10-percent of the cells in your body will be human and the remaining 90-percent will be microorganisms. That makes you a "supraorganism," and it is the interactions between your human and microbial cells that go a long way towards determining your health and physical well-being, especially your resistance to infectious diseases.
The physical and emotional strains placed on the family of a childhood cancer patient can be extremely difficult, especially for siblings.
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that members of its senior leadership and scientific teams will be leading discussions and presenting data from its novel Hedgehog pathway inhibitor program – an emerging area of cancer research – at several upcoming conferences.
› Verified 2 days ago